Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
APX3330
APX2009 and APX2014
Phentolamine Ophthalmic Solution 0.75%
Scientific Posters and Publications
Partnerships
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia
Completed
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
All SEC Filings
Investors
Investors
Overview
News / Events
Overview
Press Releases
Events
Email Alerts
Company Information
Overview
Presentations
Management Team
Contacts
FAQ
Financial Information
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Contacts
RSS News Feed
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10-Q
10KSB
10QSB
25
3
4
4/A
424A
424B3
424B4
424B5
425
5
8-A12B
8-A12G
8-K
8-K/A
ARS
CERT
CERTAMX
CORRESP
CT ORDER
D
DEF 14A
DEF 14C
DEFA14A
DEFM14A
EFFECT
FWP
NT 10-Q
POS AM
PRE 14A
PRE 14C
PRER14A
PRER14C
REGDEX
S-3
S-3/A
S-4
S-4/A
S-8
SB-2
SB-2/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SEC STAFF LETTER
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Date
Form
Description
PDF
XBRL
Pages
10/09/20
425
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
4
10/02/20
SEC STAFF LETTER
1
10/02/20
EFFECT
Notice of Effectiveness
1
10/02/20
424B3
Prospectus filed pursuant to Rule 424(b)(3)
618
09/30/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
09/30/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
09/30/20
S-4/A
Registration of securities issued in business combination transactions
Documents
EX-23.1
EX-23.5
EX-99.1
EX-99.5
EX-99.11
635
09/24/20
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
2
09/16/20
S-4/A
Registration of securities issued in business combination transactions
Documents
EX-23.1
EX-23.5
EX-99.5
631
09/15/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
4
19
20
21
22
23
24
25
26
27
28